Alnylam Fails to Revive Patent Infringement Suit Against Moderna

Alnylam Pharmaceuticals Inc. won’t get another chance at its patent infringement suit against Moderna Inc. over its mRNA Covid-19 vaccine, a federal appeals court ruled Wednesday.

The pharmaceutical company failed to convince the US Court of Appeals for the Federal Circuit that a Delaware district court erred in adopting a definition from Alnylam’s patent specification related to a chain of carbon atoms, Judge Richard Gary Taranto said.

Alnylam sued Moderna for allegedly infringing two of the pharmaceutical company’s vaccine-related patents, Nos. 11,382,979 and 11,246,933. Alnylam specifically claimed Moderna’s vaccine contained a molecule that’s covered by the asserted patents. ...